药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
3,7,11,15-tetramethyl-hexadecan-1-ol
Bendamustine
The serum concentration of Bendamustine can be increased when it is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ginsenoside Rb1
The excretion of Belantamab mafodotin can be decreased when combined with Ginsenoside Rb1.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ataluren
The excretion of Belantamab mafodotin can be decreased when combined with Ataluren.
3,7,11,15-tetramethyl-hexadecan-1-ol
Odesivimab
The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Odesivimab.
3,7,11,15-tetramethyl-hexadecan-1-ol
Maftivimab
The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Maftivimab.
3,7,11,15-tetramethyl-hexadecan-1-ol
Atoltivimab
The risk or severity of adverse effects can be increased when Belantamab mafodotin is combined with Atoltivimab.
3,7,11,15-tetramethyl-hexadecan-1-ol
Zenocutuzumab
The risk or severity of adverse effects can be increased when Zenocutuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Naratuximab emtansine
The risk or severity of adverse effects can be increased when Naratuximab emtansine is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Lorukafusp alfa
The risk or severity of adverse effects can be increased when Lorukafusp alfa is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Lulizumab pegol
The risk or severity of adverse effects can be increased when Lulizumab pegol is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Pinatuzumab vedotin
The risk or severity of adverse effects can be increased when Pinatuzumab vedotin is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Vesencumab
The risk or severity of adverse effects can be increased when Vesencumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Tomaralimab
The risk or severity of adverse effects can be increased when Tomaralimab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ladiratuzumab vedotin
The risk or severity of adverse effects can be increased when Ladiratuzumab vedotin is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
GMA-161
The risk or severity of adverse effects can be increased when GMA-161 is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Pidilizumab
The risk or severity of adverse effects can be increased when Pidilizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Istiratumab
The risk or severity of adverse effects can be increased when Istiratumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Evinacumab
The risk or severity of adverse effects can be increased when Evinacumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Sofituzumab vedotin
The risk or severity of adverse effects can be increased when Sofituzumab vedotin is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Valanafusp alfa
The risk or severity of adverse effects can be increased when Valanafusp alfa is combined with Belantamab mafodotin.